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Abstract
The Cri du Chat syndrome (CdCS) is a genetic disease resulting from a deletion of variable size
occurring on the short arm of chromosome 5 (5p-). The incidence ranges from 1:15,000 to
1:50,000 live-born infants. The main clinical features are a high-pitched monochromatic cry,
microcephaly, broad nasal bridge, epicanthal folds, micrognathia, abnormal dermatoglyphics, and
severe psychomotor and mental retardation. Malformations, although not very frequent, may be
present: cardiac, neurological and renal abnormalities, preauricular tags, syndactyly, hypospadias,
and cryptorchidism. Molecular cytogenetic analysis has allowed a cytogenetic and phenotypic map
of 5p to be defined, even if results from the studies reported up to now are not completely in
agreement. Genotype-phenotype correlation studies showed a clinical and cytogenetic variability.
The identification of phenotypic subsets associated with a specific size and type of deletion is of
diagnostic and prognostic relevance. Specific growth and psychomotor development charts have
been established. Two genes, Semaphorin F (SEMAF) and δ-catenin (CTNND2), which have been
mapped to the "critical regions", are potentially involved in cerebral development and their deletion
may be associated with mental retardation in CdCS patients. Deletion of the telomerase reverse
transcriptase (hTERT) gene, localised to 5p15.33, could contribute to the phenotypic changes in
CdCS. The critical regions were recently refined by using array comparative genomic hybridisation.
The cat-like cry critical region was further narrowed using quantitative polymerase chain reaction
(PCR) and three candidate genes were characterised in this region. The diagnosis is based on typical
clinical manifestations. Karyotype analysis and, in doubtful cases, FISH analysis will confirm the
diagnosis. There is no specific therapy for CdCS but early rehabilitative and educational
interventions improve the prognosis and considerable progress has been made in the social
adjustment of CdCS patients.
Disease name/synonyms
Cri du Chat syndrome
5p deletion
Definition
Cri du Chat Syndrome (CdCS) is a genetic disease result-
ing from a deletion of the short arm of chromosome 5
(5p-). Its clinical and cytogenetic aspects were first
described by Lejeune et al. in 1963 [1]. The most impor-
tant clinical features are a high-pitched cat-like cry (hence
the name of the syndrome), distinct facial dysmorphism,
microcephaly and severe psychomotor and mental retar-
dation. The size of the deletion ranges from the entire
short arm to the region 5p15 [2]. Simmons et al. reported
a deletion size ranging from 5 to 40 Mb [3].
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CdCS is a rare disease with an incidence ranging from
1:15,000 [4] to 1:50,000 [5] live-born infants. Niebuhr [5]
found a prevalence of around 1:350 among over 6,000
mentally retarded people, Duarte et al. [6] found a preva-
lence of 1:305 among 916 patients attending genetic
counselling services and analysed cytogenetically.
Clinical description
The clinical features at birth are low weight (mean weight
2614 g), microcephaly (mean head circumference 31.8
cm), round face (83.5%), large nasal bridge (87.2%),
hypertelorism (81.4%), epicanthal folds (90.2%), down-
ward slanting palpebral fissures (56.9%), down-turned
corners of the mouth (81.0%), low-set ears (69.8%),
micrognathia (96,7%), abnormal dermatoglyphics (trans-
verse flexion creases) (92%) and the typical cry (95.9%)
[1,5,7-19] (percentages from the Italian CdCS Registry
[19]) (Fig. 1A,B). Neonatal problems are asphyxia, cyan-
otic crises, impaired suction and hypotonia. Severe psy-
chomotor retardation becomes evident during the first
year of life. Malformations, although not very frequent,
may be present: cardiac, neurological and renal abnormal-
ities, preauricular tags, syndactyly, hypospadias, and cryp-
torchidism. Recurrent respiratory and intestinal infections
are reported during the first years of life, although higher
sensibility to infections is not reported [20].
The characteristic cat-like cry is probably due to anomalies
of the larynx (small, narrow, diamond-shaped) and of the
epiglottis (flabby, small, hypotonic), as well as to neuro-
logical, structural and functional alterations [5]. Malfor-
mations of the cranial base suggest associated anomalies
of the brain (rhombencephalic region) and larynx during
embryonal development [21].
Specific growth charts for CdCS, based on a multicentre
study carried out on 374 patients from the United States,
Italy, the United Kingdom and Australia, confirmed the
existence of prenatal and postnatal growth retardation
[22]. For all ages, median head circumference and weight
are near or below the 2nd and 5th percentile, respectively.
Height is less affected than weight from birth up to 2 years
of age in both sexes. This trend continues until later in life,
especially in males. The low weight may be attributed to
feeding difficulties and gastroesophageal reflux, both of
which are frequent in the first years of life [23]. On the
other hand, the slender body shape of many adolescent
and adult patients [5,9,14,24] may also be related to the
syndrome.
The following features develop with age: the face becomes
long and narrow (70.8%), the supra-orbital arch promi-
nent (31.0%), the philtrum short (87.8%), the lower lip
full (45.2%), dental malocclusion (open bite) (75.0%)
(Fig. 1C,D), palpebral fissures tend to become horizontal
(70.2%), divergent strabismus is frequent (44.7%), meta-
carpi (82.6%) and metatarsi (75.0%) are short resulting in
small hands and feet, and prematurely grey hair may be
observed (30.4%) [5,7-19,24-28] (percentages from the
Italian CdCS Registry [19]).
Myopia and cataract have been reported. Hypersensitivity
of the pupil to methacholine and resistance to mydriatics,
probably due to a defect of the pupil dilator muscle, have
also been described [29,30]. These features have also been
found in four patients with Goldenhar's syndrome associ-
ated with CdCS [31,32]. Scoliosis, flat foot, pes varus,
inguinal hernia and diastasis recti are frequent. Two
patients with joint hyperextensibility, skin hyperelasticity
and other features of Ehlers-Danlos syndrome [5], and
one patient with both clinical manifestations of CdCS and
Marfan syndrome have been reported [33]. A patient with
a small deletion in 5p15.33 and phenotype suggesting
Lujan-Fryns syndrome has been described [34].
Clinical features of a patient with Cri du Chat syndrome at age of 8 month (A), 2 years (B), 4 years ( ) and 9 years 6/12 (D)Figure 1
Clinical features of a patient with Cri du Chat syndrome at 
age of 8 months (A), 2 years (B), 4 years (C) and 9 years 6/12 
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adolescent patients. Sexual development is generally nor-
mal in both sexes. A single case of procreation in a CdCS
patient (a mother and a daughter with the typical syn-
drome) has been reported [35].
With age, muscle hypotonia is replaced by hypertonia,
and microcephaly becomes more evident. Convulsive cri-
ses are rare at all ages. Atrophy of the brainstem mainly
involving the pons, cerebellum, median cerebellar pedun-
cles and cerebellar white matter has been revealed by mag-
netic nuclear resonance imaging [36,37]. A CdCS child
with an arachnoid cyst, causing triventricular hydroceph-
alus by obstruction of the aqueduct of Silvius, has been
reported [38]. Metabolic anomalies have been described
in CdCS patients: a defect in the synthesis of purine nucle-
otides (important neuromediators involved in brain
development) [39,40] and clinical features associated
with non-ketotic hyperglycinaemia, infantile spasms,
hypsarrhythmia and brain heterotopia have been
reported in a patient with a 5p deletion and typical CdCS
[41].
Developmental and behavioural profile
The limited data available about the psychomotor devel-
opment indicated a severe psychomotor and mental retar-
dation in all patients [5,25]. Prognosis is better for home-
reared patients who underwent an early educational pro-
gram [42-44]. Progress in verbal development is particu-
larly slow [5,45]. Patients' ability to comprehend speech is
better than their ability to communicate [46].
A study on psychomotor development was carried out on
91 patients from the Italian Registry [18,47], using the
Denver Developmental Screening Test II (DDST II) [48].
This test showed the percentile distribution of patients on
the basis of the age of achievement of developmental
milestones [47]. A specific psychomotor development
chart has been established. Data from the Italian series
show that half of the patients walk by themselves at three
years old and that all learn to walk later; with regard to the
language, 25% of the children are able to make short sen-
tences at 4.5 years old, 50% at 5.5 and almost all the chil-
dren make short sentences before the age of 10; 50% of
the patients feed themselves with a spoon at 3.5 years old
and dress at 5 [19]. Although these patients have a range
of severe developmental retardation, they can achieve
many skills in childhood and continue to learn. This sug-
gests that today's CdCS patients have a better outcome
than those in the past [19].
CdCS children have mostly a gentle and affectionate per-
sonality. Hyperactivity is present in about 50% of patients
and sometimes coexists with aggressiveness, which can be
modified with adequate educational programs
[5,10,42,49]. The behavioural profile of 27 patients stud-
ied by Cornish and Pigram [44] showed self-injury, repet-
itive movements, hypersensitivity to sounds, clumsiness
and obsessive attachment to objects. Hyperactivity and
distractibility seems specific to CdCS, if compared to
Prader-Willi and Smith-Magenis syndromes [50]. A survey
of the prevalence of stereotypy, self-injury and aggression
in CdCS children and young adults has been recently car-
ried out by Collins and Cornish [51]. A low level of object-
directed behaviour may be an early precursor of hyperac-
tivity, distractibility and stereotypy in older individuals
[52]. Nevertheless, early educational interventions and
the involvement of families and caregivers allow these
behaviours to be improved [19,42].
Aetiology
The introduction of molecular cytogenetic analysis (Fluo-
rescence In Situ Hybridisation, FISH) has allowed the
cytogenetic and phenotypic map of 5p to be defined
[2,53-56]. Analysis of 80 patients and 148 parents from
the Italian Registry of CdCS revealed: a 5p terminal dele-
tion (62 patients: 77.5%), an interstitial deletion (seven
patients: 8.75%), a de novo translocation (four patients:
5%), a familial translocation (three patients: 3.75%), a
mosaic with two rearranged cell lines (three patients:
3.75%) and a deletion originating from a paternal inver-
sion (one patient: 1.25%). The breakpoints range from
p13 to p15.2 (Fig. 2) [56]. This region contains a large
number of repetitive sequences that may account for its
instability [55,57]. Molecular analysis showed that the
deleted chromosome is paternal in most cases: 20/25
(80%) [58], 10/12 (83.3%) [54], 55/61 (90.2%) [56].
The recent studies and observations of Italian patients
suggest that partial aneusomy syndromes like CdCS result
from abnormal gene dosage (haploinsufficiency) involv-
ing a large number of contiguous genes [3,55,56,59].
Other mechanisms, such as gene inactivation due to the
position effect or rupture of a very large gene, have also
been suggested [60].
A gene for chondrocalcinosis [61] and a gene for asthma
[62] have been mapped to 5p15.2. The human Sema-
phorin F gene (SEMAF) covering at least 10% of this
region has been cloned [63]. Due to its role in guiding
axons or migrating neuronal precursors during cortical
development in mice, it has been suggested that the
SEMAF deletion may be responsible for some of the fea-
tures of CdCS. Another gene, human δ-catenin
(CTNND2), has also been mapped to 5p15.2 [59]. δ-cat-
enin is a protein involved in cell motility and is expressed
early in neuronal development. δ-catenin deletion seems
to correlate with mental retardation in patients with a ter-
minal deletion in this area [59]. δ-catenin knockout micePage 3 of 9
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firming the critical role of this gene in brain function [64].
The results of a recent study in CdCS patients suggest that
haploinsufficiency of the telomerase reverse transcriptase
(hTERT) gene, localised to 5p15.33, could contribute to
the heterogeneous phenotype of CdCS. hTERT is the rate-
limiting component for the telomerase activity that is
essential for telomere-length maintenance and sustained
cell proliferation [65].
Genotype-phenotype correlation
Although CdCS is a well-defined clinical entity, individu-
als with 5p deletion show phenotypic and cytogenetic var-
iability. A few studies, sometimes giving conflicting
results, have been performed to correlate the clinical pic-
ture with the deletion size [5,24,56,66]. A more severe
phenotype and cognitive impairment was reported to be
associated with a larger deletion [10,67].
The fact that the phenotype is well recognisable, in spite
of the variability in deletion size, has led to the hypothesis
that a critical region causes the characteristic clinical pic-
ture when present in a hemizygous situation: Niebuhr
located this region in a narrow area around 5p15.2 [5,68].
Such an assumption was supported by findings of individ-
uals with a deletion that did not include 5p15.2, who
Phenotypic map of 5pFigure 2
Phenotypic map of 5p. Vertical lines indicate the critical regions for the cry in p15.3, and for the other signs of Cri du Chat syn-
drome in p15.2. Vertical lines in p15.1, p14 and p13 refer to clinical symptoms reported in individual families with interstitial 
deletions.
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[69,70], or were completely normal [71].
Molecular-cytogenetic analysis allowed Overhauser et al.
[2] and Gersh et al. [53] to identify two distinct regions,
one for the typical cry in 5p15.3, and another for the other
clinical characteristics in 5p15.2. Church et al. [54] distin-
guished several critical regions: a region for speech retar-
dation, one for the typical cry, one for face dysmorphisms
in childhood and one for face dysmorphisms in adult-
hood (Fig. 2).
A genotype-phenotype correlation study has been carried
out in 80 patients from the Italian CdCS Registry. All of
them underwent FISH analysis [56]. The results con-
firmed the importance of deletion of the critical region for
manifestation of the CdCS clinical features. However,
they also showed a clinical and cytogenetic variability and
highlighted a correlation between clinical severity, and
the size and type of deletion. In fact, in 62 patients with
terminal deletion, the degree of severity (for microceph-
aly, dysmorphism and psychomotor retardation) has
been demonstrated to vary between patients with a small
deletion in 5p15.2 and 5p15.1, and patients with a larger
deletion. The condition of patients with a deletion in
5p13 appeared particularly severe (Fig. 2).
The variability correlated with the type of deletion in
patients with an interstitial deletion, unbalanced translo-
cation resulting in 5p deletion, mosaicism and other rare
rearrangements. The study of patients with an interstitial
deletion and with a small terminal deletion has enabled
the existence of two distinct critical regions (one for dys-
morphisms, microcephaly and mental retardation in
p15.2, and the other for the typical cry in p15.3) to be
confirmed. Moreover, this study allowed the cry region
defined by Overhauser et al. [2] to be narrowed distally
and supported the hypothesis of a distinct region for
speech retardation in p15.3 [54]. Furthermore, two
patients who showed an interstitial deletion and a termi-
nal deletion that did not include the critical region and
did not show CdCS clinical features, confirmed that not
all 5p deletions result in the CdCS phenotype [56,69,70].
In patients with an unbalanced translocation resulting in
5p deletion, the partial trisomy of the other involved chro-
mosome may influence the clinical features, even if the
CdCS phenotype prevails [72]. Three patients with mosa-
icism showed two rearranged cell lines: one with both cell
lines deleted, the others with a deleted and a duplicated
cell line. In the latter, the CdCS phenotype prevailed over
the effect of the partial 5p trisomy present in part of the
cells. The patient with the largest duplication had a mild
clinical picture, suggesting compensation between deleted
and duplicated cell lines [73]. Kitsiou et al. reported a
patient with three cell lines in the same tissue: del 5p, dup
5p and a normal one. The mild phenotype in this patient
could be mainly due to the normal cell line. However, the
duplicated cell line may have contributed to the pheno-
type through the duplication of the critical CdCS region
[73,74].
The deleted chromosome was mainly of paternal origin
[54,56,58]: no phenotypic differences caused by imprint-
ing effects were observed in the Italian group of patients
[56].
The combination of FISH, comparative genome hybridi-
sation (CGH) and cytogenetic analysis of a patient with
dup5q/del5p confirmed that the characteristic cry was due
to the deletion at 5p15.3 [75]. Recently Rossi et al. [76],
using FISH analysis with bacterial artificial chromosome
(BAC) clones in a patient without typical CdCS features,
were able to correlate cat-like cry and mild mental retarda-
tion with a deletion in 5p15.31, 8.5 Mb away from the
short arm telomere. Zhang et al. [77], by using array CGH,
refined the CdC critical regions and confirmed the corre-
lation between the severity of mental retardation and the
deletion size and type. Using quantitative polymerase
chain reaction (PCR), Wu et al. [78] narrowed the critical
region for the cat-like cry to a short 640 Kb region and
characterised three candidate genes in this region. Har-
vard et al. [79] found, in a subject with an autism spec-
trum disorder, a de novo cryptic microdeletion involving
5p15.2.
The identification of phenotypic subsets associated with
specific deletions may be of great diagnostic and prognos-
tic relevance. Furthermore, clinical examination com-
bined with molecular analysis of the deletion results in a
more personalised evaluation of the patients, which is
useful for rehabilitative and educational programs [56].
Diagnostic methods
The diagnosis is first of all clinical, based on typical char-
acteristics such as facial dysmorphisms (facial gestalt),
transverse flexion creases, hypotonia in combination with
the peculiar cat-like cry. The first test to perform is karyo-
type analysis, which will confirm the diagnosis. In doubt-
ful cases, when there is a conflict between the clinical
suspicion and an apparently normal karyotype result,
FISH analysis should be performed [19,34,56,76,80-83].
The importance of FISH for a precise diagnosis of 5p dele-
tions must be emphasised. In the Italian series (80
patients), seven of the patients had not been correctly
diagnosed by routine cytogenetics. FISH revealed that five
of these patients had an interstitial deletion, one had a
small terminal deletion and one had mosaicism [56].
Subtelomeric FISH allows 5p cryptic chromosomal rear-Page 5 of 9
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as array CGH and quantitative PCR, mainly used for
research purposes, allow a more precise definition of
breakpoints and microrearrangements [77-79].
Differential diagnosis
The clinical features of CdCS patients are not specific if
considered separately but, if valued as a whole, they result
in a distinct phenotype which, together with the peculiar
cry, allows the diagnosis to be suspected at birth. Karyo-
type analysis of the peripheral blood will confirm the
diagnosis.
In the mild cases that can escape the diagnosis or in older
patients, it will be the clinical picture (and, above all, the
voice that remains abnormal) and the psychomotor retar-
dation that will lead to carrying out of cytogenetic and
molecular cytogenetic analyses.
Genetic counselling
The risk of recurrence is practically negligible for the cases
of a de novo deletion, which are the most frequent. How-
ever, the possibility of gonadal mosaicism in one of the
parents cannot be excluded, even if no recurrence has
been reported up to now. It is higher for cases of balanced
familial translocation. The reproductive risk for carriers of
translocations involving 5p has been defined by evalua-
tion of personal and reviewed data from 54 pedigrees
[72]. The same study showed that the risk of unbalanced
offspring (according to the pachytene configuration and
5p breakpoint localisation) ranged from 8.7% to 18.8%.
The risk for male and female carriers was similar [72]. In
these cases, prenatal diagnosis is appropriate.
Antenatal diagnosis
Prenatal diagnosis by cytogenetic and molecular cytoge-
netic analyses has been reported in some cases with previ-
ous CdCS child, in which the syndrome resulted from a
familial balanced translocation [84-88]. Prenatal diagno-
sis of de novo 5p deletions is not frequent. In two cases it
has been performed on the basis of a nonimmune foetal
hydrops [89,90], and in another, on the basis of an abnor-
mal ultrasound finding of isolated moderate bilateral ven-
triculomegaly [91]. Foetal choroid plexus cysts and/or
abnormal maternal serum human chorionic gonadotro-
pin (hCG) values in association with CdCS have been
reported [92-95]. Chen et al. reported prenatal diagnosis
of a foetus with 5p-mosaicism in a case involving
advanced maternal age and carried out a review of the lit-
erature [88]. In their patient, the mosaic distal 5p deletion
was found in association with sonographic markers such
as microcephaly and cerebellar hypoplasia [88]. Prenatal
diagnosis of the 5p deletion in association with Dandy-
Walker syndrome and agenesis of the corpus callosum has
been reported [96].
However, it should be noted that not all 5p deletions
result in the CdCS phenotype: subjects with short termi-
nal deletions in 5p15.3 may show only a mild or moder-
ate psychomotor retardation [69,70,76,97,98]. Moreover,
an interstitial and apparently unbalanced deletion in
5p14, detected by prenatal diagnosis indicated for
advanced maternal age and traced through six individuals
in three generations, resulted in a completely normal phe-
notype [71].
Management
There is no specific treatment for CdCS as the cerebral
damage resulting from the mutation occurs in the early
stages of the embryonal development. Nevertheless,
patients benefit from rehabilitative programs, which
should be started as soon as possible and involve close
collaboration with families, who must be supported psy-
chologically. Moreover, it is important to give to the fam-
ilies updated information about the syndrome, also
available through CdCS Support Groups.
Neonatal problems can generally be treated in neonatal
pathology departments and intensive treatment is rarely
necessary. Breast feeding is possible. For newborns with
difficulties in suction and swallowing, physical therapy
should start in the first weeks of life. If malformations are
present, neonatologists and paediatricians should suggest
diagnostic investigations and specialist examinations. It is
important to highlight the risk of anaesthesiological prob-
lems (intubation difficulties) linked to larynx and epiglot-
tis malformations [99,100]. Intubation difficulties were
observed in three cases in the Italian series, but at an older
age many patients underwent general anaesthesia without
complications [19].
Early rehabilitation (physical therapy, psychomotricity,
speech therapy) is recommended for the neurological
problems such as psychomotor and speech retardation. As
some patients have sensory-neural deafness and speech
retardation, audiometric examination should be carried
out on all CdCS children. All advised vaccinations are rec-
ommended.
Upbringing and rehabilitation are equally important for
improvement of the social adaptation of the patients.
Guidelines for treatment and follow-up have been
reviewed elsewhere [17-19,101].
Prognosis
After the first years of life, the survival expectation is high
and morbidity is low. The mortality in the series studied
by Niebuhr was about 10%, 75% of which occurred dur-
ing the first months of life, and up to 90% within the first
year [5]. Among the cases described in this study, three
patients have lived to be over 50 years of age. UpdatedPage 6 of 9
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history of CdCS in a large series of Italian patients [19].
Recent improvements in management of patients with
CdCS, with the application of rehabilitative programs,
have led to increased psychomotor development,
improved autonomy and better social adaptation [19].
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